Management of chronic insomnia in elderly persons

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 2, 2006, Pages 168-192

  Bain, Kevin T ^a  

^a excelleRx Inc   (United States)

Author keywords

chronic insomnia; elderly; nonpharmacologic management; pharmacologic management; sedative hypnotic

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIHISTAMINIC AGENT; ATOMOXETINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; CHLORAL HYDRATE; CORTICOSTEROID; DILTIAZEM; DIURETIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; EPHEDRINE; HYPNOTIC SEDATIVE AGENT; MELATONIN; MELATONIN AGONIST; MELATONIN DERIVATIVE; METHYLDOPA; METHYLPHENIDATE; METOPROLOL; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NADOLOL; PHENYLEPHRINE; PHENYTOIN; THEOPHYLLINE; THYROID HORMONE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ACCIDENT PRONENESS; AGED; ANTEROGRADE AMNESIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CACHEXIA; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION DISORDER; DIARRHEA; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELDERLY CARE; EVIDENCE BASED MEDICINE; FALLING; FATIGUE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; FRACTURE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFORMATION RETRIEVAL; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; NAUSEA; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; SEDATION; SOMNOLENCE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT DURATION; URINE RETENTION; WEIGHT GAIN; XEROSTOMIA;

AGED; CHRONIC DISEASE; COGNITIVE THERAPY; DIETARY SUPPLEMENTS; DRUGS, NON-PRESCRIPTION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIALS; RELAXATION TECHNIQUES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33745968178     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.06.006     Document Type: Article

References (173)

1. Mathews D. Review of insomnia: The sleep cycle and treatment options. Pharm Times 69 (2003) 75-87
2. Sateia M.J., and Nowell P.D. Insomnia. Lancet 364 (2004) 1959-1973
3. Sateia M.J., Doghramji K., Hauri P.J., and Morin C.M. Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 23 (2000) 243-308
4. Available at:. National Sleep Foundation. Summary of findings. 2005 Sleep in America Poll. Accessed (November 21, 2005). http://www.sleepfoundation.org/_content/hottopics/2005_summary_of_findings.pdf
5. Maggi S., Langlois J.A., Minicuci N., et al. Sleep complaints in community-dwelling older persons: Prevalence, associated factors, and reported causes. J Am Geriatr Soc 46 (1998) 161-168
6. (Suppl). Simonson W. Pharmacists' role in recognizing and managing patients with insomnia. Pharm Times 70 (2004) S1-S8
7. Foley D., Ancoli-Israel S., Britz P., and Walsh J. Sleep disturbances and chronic disease in older adults: Results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 56 (2004) 497-502
8. Foley D.J., Monjan A.A., Brown S.L., et al. Sleep complaints among elderly persons: An epidemiologic study of three communities. Sleep 18 (1995) 425-432
9. Foley D.J., Monjan A., Simonsick E.M., et al. Incidence and remission of insomnia among elderly adults: An epidemiologic study of 6,800 persons over three years. Sleep 22 Suppl 2 (1999) S366-S372
10. Zammit G.K., Weiner J., Damato N., et al. Quality of life in people with insomnia. Sleep 22 Suppl 2 (1999) S379-S385
11. Hatoum H.T., Kong S.X., Kania C.M., et al. Insomnia, health-related quality of life and healthcare resource consumption. A study of managed-care organisation enrollees. PharmacoEconomics 14 (1998) 629-637
12. Dopheide J.A., and Stimmel G.L. Sleep disorders. In: Koda-Kimble M.A., Young L.Y., Kradjan W.A., et al. (Eds). Applied Therapeutics: The Clinical Use of Drugs. 8th ed. (2005), Lippincott, Williams & Wilkins, Philadelphia, Pa 1-22
13. Ford D.E., and Kamerow D.B. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?. JAMA 262 (1989) 1479-1484
14. Breslau N., Roth T., Rosenthal L., and Andreski P. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 39 (1996) 411-418
15. Weissman M.M., Greenwald S., Nino-Murcia G., and Dement W.C. The morbidity of insomnia uncomplicated by psychiatric disorders. Gen Hosp Psychiatry 19 (1997) 245-250
16. Kapur V.K., Redline S., Nieto F.J., et al., Sleep Heart Health Research Group. The relationship between chronically disrupted sleep and healthcare use. Sleep 25 (2002) 289-296
17. Jordan J.M., Bernard S.L., Callahan L.F., et al. Self-reported arthritis-related disruptions in sleep and daily life and the use of medical, complementary, and self-care strategies for arthritis: The National Survey of Self-care and Aging. Arch Fare Med 9 (2000) 143-149
18. Simon G.E., and VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 154 (1997) 1417-1423
19. Kuppermann M., Lubeck D.P., Mazonson P.D., et al. Sleep problems and their correlates in a working population. J Gen Intern Med 10 (1995) 25-32
20. Leger D., Guilleminault C., Bader G., et al. Medical and socio-professional impact of insomnia. Sleep 25 (2002) 625-629
21. Garbarino S., De Carli F., Nobili L., et al. Sleepiness and sleep disorders in shift workers: A study on a group of Italian police officers. Sleep 25 (2002) 648-653
22. Brassington G.S., King A.C., and Bliwise D.L. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 48 (2000) 1234-1240
23. Wolf S.L., Barnhart F.I.X., Kutner N.G., et al. Selected as the best paper in the 1990s: Reducing frailty and falls in older persons: An investigation of tai chi and computerized balance training. J Am Geriatr Soc 51 (2003) 1794-1803
24. Avidan A.Y., Fries B.E., James M.L., et al. Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53 (2005) 955-962
25. Ancofi-Israel S., and Cooke J.R. Prevalence and comorbidity of insomnia and effect on functioning in elderly populations. J Am Geriatr Soc 53 Suppl 7 (2005) S264-S271
26. Gillin J.C., and Byerley W.F. Drug therapy: The diagnosis and management of insomnia. N Engl J Med 322 (1990) 239-248
27. Buysse D.J. Diagnosis and classification of insomnia disorders. In: Szuba M.P., Moss J.D., and Dinges D.F. (Eds). Insomnia: Principles and Management (2003), Cambridge University Press, Cambridge, UK 3-22
28. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition (2000), American Psychiatric Association, Washington, DC
29. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. (2005), American Academy of Sleep Medicine, Westchester, Ill
30. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). 6th ed. (2004), Practice Management Information Corporation, Los Angeles, Calif.
31. McCall W.V., Fleischer Jr. A.B., and Feldman S.R. Diagnostic codes associated with hypnotic medications during outpatient physician-patient encounters in the United States from 1990-1998. Sleep 25 (2002) 221-223
32. Nowell P.D., Buysse D.J., Reynolds III C.F., et al. Clinical factors contributing to the differential diagnosis of primary insomnia and insomnia related to mental disorders. Am J Psychiatry 154 (1997) 1412-1416
33. [pubfished correction appears in N Engl J Med. 2005;353: 2827]1. Silber M.H. Clinical practice. Chronic insomnia. N Engl J Med 353 (2005) 803-810
34. Buysse D.J., Reynolds III C.F., Kupfer D.J., et al. Clinical diagnoses in 216 insomnia patients using the International Classification of Sleep Disorders (ICSD), DSM IV and ICD-10 categories: A report from the APA/ NIMH DSM-IV field trial. Sleep 17 (1994) 630-637
35. Buysse D.J., Reynolds III C.F., Hauri P.J., et al. Diagnostic concordance for DSM-IV sleep disorders: A report from the APA/NIMH DSM-IV field trial. Am J Psychiatry 151 (1994) 1351-1360
36. Ohayon M.M. Prevalence of DSM-IV diagnostic criteria of insomnia: Distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 31 (1997) 333-346
37. [serial online]. Chavez B. Pharmacotherapy in managing insomnia: Assessing patient needs and outcomes. US Pharm 2 (2005) HS23-HS26
38. Dopheide J.A., and Kushida C.A. Newer options in the management of insomnia. US Pharm 30 (2005) 102-112
39. [published correction appears in Arch Intern Med. 2004;164:298]. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med. 163 (2003) 2716-2724
40. McCall W.V., D'Agostino Jr. R.D., and Dunn A. A meta-analysis of sleep changes associated with placebo in hypnotic clinical trials. Sleep Med 4 (2003) 57-62
41. McCall W.V. Diagnosis and management of insomnia in older people. J Am Geriatr Soc 53 Suppl 7 (2005) S272-S277
42. Harvey A.G., and Tang N.K. Cognitive behaviour therapy for primary insomnia: Can we rest yet?. Sleep Med Rev 7 (2003) 237-262
43. Chesson Jr. A.L., Anderson W.M., Litmer M., et al., Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine report. Sleep 22 (1999) 1128-1133
44. Morin C.M., Culbert J.P., and Schwartz S.M. Nonpharmacological interventions for insomnia: A meta-analysis of treatment efficacy. Am J Psychiatry 151 (1994) 1172-1180
45. Murtagh D.R., and Greenwood K.M. Identifying effective psychological treatments for insomnia: A meta-analysis. J Consult Clin Psychol 63 (1995) 79-89
46. McClusky H.Y., Milby J.B., Switzer P.E., et al. Efficacy of behavioral versus triazolam treatment in persistent sleeponset insomnia. Am J Psychiatry 148 (1991) 121-126
47. Smith M.T., Perlis M.L., Park A., et al. Comparative metaanalysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry 159 (2002) 5-11
48. Jacobs G.D., Pace-Schott E.F., Stickgold R., and Otto M.W. Cognitive behavior therapy and pharmacotherapy for insomnia: A randomized controlled trial and direct comparison. Arch Intern Med 164 (2004) 1888-1896
49. Morin C.M., Colecchi C., Stone J., et al. Behavioral and pharmacological therapies for late-fife insomnia: A randomized controlled trial. JAMA 281 (1999) 991-999
50. Hauri P.J. Can we mix behavioral therapy with hypnotics when treating insomniacs?. Sleep 20 (1997) 1111-1118
51. Espie C.A., Inglis S.J., Tessier S., and Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: Implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther 39 (2001) 45-60
52. Edinger J.D., Wohlgemuth W.K., Radtke R.A., et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: A randomized controlled trial. JAMA 285 (2001) 1856-1864
53. Holbrook A., Crowther R., Lotter A., and Endeshaw Y. The role of benzodiazepines in the treatment of insomnia: Meta-analysis of benzodiazepine use in the treatment of insomnia. J Am Geriatr Soc 49 (2001) 824-826
54. Chambers M.J. Therapeutic issues in the behavioral treatment of insomnia. Prof Psychol Res Pract 23 (1992) 131-138
55. Bouchard S., Bastien C., and Morin C.M. Self-efficacy and adherence to cognitive-behavioral treatment of insomnia. Behav Sleep Med 1 (2003) 187-199
56. Sloan E.P., Hauri P., Bootzin R., et al. The nuts and bolts of behavioral therapy for insomnia. J Psychosom Res 37 Suppl 1 (1993) 19-37
57. Nowell P.D., Mazumdar S., Buysse D.J., et al. Benzodiazepines and zolpidem for chronic insomnia: A metaanalysis of treatment efficacy. JAMA 278 (1997) 2170-2177
58. Mendelson W.B., Roth T., Cassella J., et al. The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. Sleep Med Rev 8 (2004) 7-17
59. Hohagen F., Kappler C., Schramm E., et al. Sleep onset insomnia, sleep maintaining insomnia and insomnia with early morning awakening-temporal stability of subtypes in a longitudinal study on general practice attenders. Sleep 17 (1994) 551-554
60. Benca R.M. Diagnosis and treatment of chronic insomnia: A review. Psychiatr Serv 56 (2005) 332-343
61. Sproule B.A., Busto U.E., Buckle C., et al. The use of non-prescription sleep products in the elderly. Int J Geriatr Psychiatry 14 (1999) 851-857
62. Jindal R.D., and Thase M.E. Treatment of insomnia associated with clinical depression. Sleep Med Rev 8 (2004) 19-30
63. Agargun M.Y., Kara H., and Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 58 (1997) 249-251
64. Zhan C., Sangl J., Bierman A.S., et al. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey. JAMA 286 (2001) 2823-2829
65. discussion 46-48. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60 Suppl 17 (1999) 28-31
66. Winokur A., Sateia M.J., Hayes J.B., et al. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study. Biol Psychiatry 48 (2000) 75-78
67. Schittecatte M., Dumont F., Machowski R., et al. Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology 46 (2002) 197-201
68. Winokur A., DeMartinis III N.A., McNally D.P., et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depres sion and insomnia. J Clin Psychiatry 64 (2003) 1224-1229
69. Montgomery I., Oswald I., Morgan K., and Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 16 (1983) 139-144
70. (Suppl). Mouret J., Lemoine P., Minuit M.P., et al. Effects of trazodone on the sleep of depressed subjects-a polygraphic study. Psychopharmacology (Berl) 95 (1988) S37-S43
71. (Suppl). Scharf M.B., and Sachais B.A. Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients. J Clin Psychiatry 51 (1990) 13-17
72. (Suppl). Ware J.C., and Pittard J.T. Increased deep sleep after trazodone use: A double-blind placebo-controlled study in healthy young adults. J Clin Psychiatry 51 (1990) 18-22
73. Yamadera H., Nakamura S., Suzuki H., and Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci 52 (1998) 439-443
74. Suzuki H., Yamadera H., Nakamura S., and Endo S. Effects of trazodone and imipramine on the biological rhythm: An analysis of sleep EEG and body core temperature. J Nippon Med Sch 69 (2002) 333-341
75. van Bemmel A.L., Havermans R.G., and van Diest R. Effects of trazodone on EEG sleep and clinical state in major depression. Psychopharmacology (Berl) 107 (1992) 569-574
76. Thase M.E., Rush A.J., Manber R., et al. Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. J Clin Psychiatry 63 (2002) 493-500
77. Rush A.J., Armitage R., Gillin J.C., et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44 (1998) 3-14
78. Brooks D., Prothero W., Bouras N., et al. Trazodone-a comparison of single night-time and divided daily dosage regimens. Psychopharmacology (Berl) 84 (1984) 1-4
79. Mashiko H., Niwa S., Kumashiro H., et al. Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: Dose-finding study with no concomitant use of hypnotic agent. Psychiatry Clin Neurosci 53 (1999) 193-194
80. Nierenberg A.A., Adler L.A., Peselow E., et al. Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151 (1994) 1069-1072
81. Nierenberg A.A., Cole J.O., and Glass L. Possible trazodone potentiation of fluoxetine: A case series. J Clin Psychiatry 53 (1992) 83-85
82. Armitage R., Yonkers K., Cole D., and Rush A.J. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Psychopharmacol 17 (1997) 161-168
83. [published correction appears in J Clin Psychiatry. 1997; 58:275]. Gillin J.C., Rapaport M., Erman M.K., et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial. J Clin Psychiatry 58 (1997) 185-192
84. Hicks J.A., Argyropoulos S.V., Rich A.S., et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180 (2002) 528-535
85. Sharpley A.I., Walsh A.E., and Cowen P.J. Nefazodone-a novel antidepressant-may increase REM sleep. Biol Psychiatry 31 (1992) 1070-1073
86. Armitage R., Rush A.J., Trivedi M., et al. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology 10 (1994) 123-127
87. Sharpley A.L., Williamson D.J., Attenburrow M.E., et al. The effects of paroxetine and nefazodone on sleep: A placebo controlled trial. Psychopharmacology (Berl) 126 (1996) 50-54
88. Wiegand M.H., Galanakis P., and Schreiner R. Nefazodone in primary insomnia: An open pilot study. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1071-1078
89. Dundar Y., Dodd S., Strobl J., et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis. Hum Psychopharmacol 19 (2004) 305-322
90. (Suppl). Roth T., and Roehrs T.A. A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry (1991) 38-41
91. Prosom [package insert] (2004), Abbott Laboratories, Abbott Park, Ill
92. Jochemsen R., and Breimer D.D. Pharmacokinetics of benzodiazepines: Metabolic pathways and plasma level profiles. Curr Med Res Opin 8 Suppl 4 (1984) 60-79
93. Jermain D.M. Sleep disorders. In: DiPiro J.T., Talbert R.L., Yee G.C., et al. (Eds). Pharmacotherapy: A Pathophysiologic Approach. 4th ed. (1999), Appleton & Lange, Stamford, Conn 1208-1218
94. Dalmane [package insert] (2000), Roche Products, Inc, Humacao, PR
95. Chung M., Hilbert J.M., Gural R.P., et al. Multiple-dose quazepamkinetics. Clin Pharmacol Ther 35 (1984) 520-524
96. Hilbert J.M., Chung M., Maier G., et al. Effect of sleep on quazepam kinetics. Clin Pharmacol Ther 36 (1984) 99-104
97. Restoril [package insert] (2004), Mallinckrodt Inc, St. Louis, Mo
98. Halcion [package insert] (2003), Pharmacia & Upjohn Company, Kalamazoo, Mich
99. Lunesta [package insert] (2005), Sepracor Inc, Marlborough, Mass
100. Krystal A.D., Walsh J.K., Laska E., et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 26 (2003) 793-799
101. Sonata [package insert] (2004), Wyeth Pharmaceuticals, Inc, Philadelphia, Pa
102. Wagner J., Wagner M.L., and Hening W.A. Beyond benzodiazepines: Alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 32 (1998) 680-691
103. Ambien [package insert] (2004), Sanofi-Synthelabo Inc, New York, NY
104. Swainston Harrison T., and Keating G.M. Zolpidem: A review of its use in the management of insomnia. CNS Drugs 19 (2005) 65-89
105. Ambien CR [package insert] (2005), Sanofi-Synthelabo Inc, New York, NY
106. Rozerem [package insert] (2005), Takeda Pharmaceuticals America, Inc, Lincolnshire, Ill
107. [published correction appears in Sleep. 2006;29:417]. Roth T., Stubbs C., and Walsh J.K. Ramelteon (TAK-375), a selective MTI/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 28 (2005) 303-307
108. Chapron D.J. Drug disposition and response in the elderly. In: Delafuente J.C., and Stewart R.B. (Eds). Therapeutics in the Elderly. 3rd ed (2000), Harvey Whitney Books, Cincinnati, Ohio 257-288
109. Bressler R., and Bahl J.J. Principles of drug therapy for the elderly patient. Mayo Clin Proc 78 (2003) 1564-1577
110. Holbrook A.M., Crowther R., Lotter A., et al. Metaanalysis of benzodiazepine use in the treatment of insomnia. CMAJ 162 (2000) 225-233
111. Short R.I., Bauwens S.F., and Landefeld C.S. Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: Placing the elderly at risk. Am J Med 89 (1990) 725-732
112. Egan M., Moride Y., Wolfson C., and Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: Prevalence, incidence and risk factors. J Am Geriatr Soc 48 (2000) 811-816
113. Llorente M.D., David D., Golden A.G., and Silverman M.A. Defining patterns of benzodiazepine use in older adults. J Geriatr Psychiatry Neurol 13 (2000) 150-160
114. Curran H.V., Collins R., Fletcher S., et al. Older adults and withdrawal from benzodiazepine hypnotics in general practice: Effects on cognitive function, sleep, mood and quality of life. Psychol Med 33 (2003) 1223-1237
115. Rummans T.A., Davis Jr. L.J., Morse R.M., and Ivnik R.J. Learning and memory impairment in older, detoxified, benzodiazepine-dependent patients. Mayo Clin Proc 68 (1993) 731-737
116. Barker M.J., Greenwood K.M., Jackson M., and Crowe S.F. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: A meta-analysis. Arch Clin Neuropsychol 19 (2004) 437-454
117. Barker M.J., Greenwood K.M., Jackson M., and Crowe S.F. An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc 11 (2005) 281-289
118. Gray S.L., Penninx B.W., Blough D.E., et al. Benzodiazepine use and physical performance in communitydwelling older women. J Am Geriatr Soc 51 (2003) 1563-1570
119. Leipzig R.M., Cumming R.G., and Tinetti M.E. Drugs and falls in older people: A systematic review and metaanalysis: I. Psychotropic drugs. J Am Geriatr Soc 47 (1999) 30-39
120. Thomas R.E. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Farn Physician 44 (1998) 799-808
121. Poyares D., Guilleminault C., Ohayon M.M., and Tufik S. Chronic benzodiazepine usage and withdrawal in insomnia patients. J Psychiatr Res 38 (2004) 327-334
122. (Suppl). Wamsley J.K., and Hunt M.A. Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. J Clin Psychiatry 52 (1991) 15-20
123. Wagner J., and Wagner M.L. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 4 (2000) 551-581
124. Perlis M.L., McCall W.V., Krystal A.D., and Walsh J.K. Longterm, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry 65 (2004) 1128-1137
125. Scharf M.B., Roth T., Vogel G.W., and Walsh J.K. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55 (1994) 192-199
126. Kummer J., Guendel L., Linden J., et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 21 (1993) 171-184
127. Asnis G.M., Chakraburtty A., DuBoff E.A., et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry 60 (1999) 668-676
128. [published correction appears in J Int Med Res. 1993 21:346]. Schlich D., L'Heritier C., Coquelin J.P., et al. Long-term treatment of insomnia with zolpidem: A multicentre general practitioner study of 107 patients. J Int Med Res 19 (1991) 271-279
129. Barbera J., and Shapiro C. Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 28 (2005) 301-318
130. Walsh J.K., Fry J., Erwin C.W., et al. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clin Drug Invest 16 (1998) 347-354
131. Elie R., Ruther E., Farr I., et al., Zaleplon Clinical Study Group. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 60 (1999) 536-544
132. Fry J., Scharf M., Mangano R., Fujimori M., and Zaleplon Clinical Study Group. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Int Clin Psychopharmacol 15 (2000) 141-152
133. Walsh J.K., Vogel G.W., Scharf M., et al. A five week, polysomnographic assessment of zaleplon 10 mg for the treatment of primary insomnia. Sleep Med 1 (2000) 41-49
134. Hedner J., Yaeche R., Emilien G., et al., Zaleplon Clinical Investigator Study Group. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. Int J Geriatr Psychiatry 15 (2000) 704-712
135. Ancoli-Israel S., Walsh J.K., Mangano R.M., and Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Print Care Companion J Clin Psychiatry 1 (1999) 114-120
136. Walsh J.K., Pollak C.P., Scharf M.B., et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 23 (2000) 17-21
137. Roth T., Walsh J.K., Krystal A., et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 6 (2005) 487-495
138. Carlson J.N., Haskew R., Wacker J., et al. Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol 415 (2001) 181-189
139. (Suppl). Erman M., Rosenberg R., and Caron Y. Polysomnographic and patient-reported evaluation of the efficacy and safety of eszopiclone in elderly subjects with chronic insomnia. Abstract. Sleep 27 (2004) S257-S258
140. Scharf M., Erman M., Rosenberg R., et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 28 (2005) 720-727
141. Available at:. Insomnia: Indiplon, IR & MR formulations. Accessed (March 13, 2006). http://www.neurocrine.com/html/clin_insomnia.html
142. Glass J., Lanctot K.L., Herrmann N., et al. Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ 331 (2005) 1169
143. Kato K., Hirai K., Nishiyama K., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 48 (2005) 301-310
144. Skene D.J., Vivien-Roels B., Sparks D.L., et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: Effect of age and Alzheimer's disease. Brain Res 528 (1990) 170-174
145. Mirmiran M., Swaab D.F., Kok J.H., et al. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 93 (1992) 151-163
146. Turek F.W., and Gillette M.U. Melatonin, sleep, and circadian rhythms: Rationale for development of specific melatonin agonists. Sleep Med 5 (2004) 523-532
147. Sack R.L., Hughes R.J., Edgar D.M., and Lewy A.J. Sleep-promoting effects of melatonin: At what dose, in whom, under what conditions, and by what mechanisms?. Sleep 20 (1997) 908-915
148. Waldhauser F., Waldhauser M., Lieberman H.R., et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 39 (1984) 307-313
149. DeMuro R.L., Nafziger A.N., Blask D.E., et al. The absolute bioavailability of oral melatonin. J Clin Pharmacol 40 (2000) 781-784
150. Di W.L., Kadva A., Johnston A., and Silman R. Variable bioavailability of oral melatonin. N Engl J Med 336 (1997) 1028-1029
151. Mendelson W.B. A critical evaluation of the hypnotic efficacy of melatonin. Sleep 20 (1997) 916-919
152. Stone B.M., Turner C., Mills S.L., and Nicholson A.N. Hypnotic activity of melatonin. Sleep 23 (2000) 663-669
153. Zhdanova I.V., and Wurtman R.J. Efficacy of melatonin as a sleep-promoting agent. J Biol Rhythms 12 (1997) 644-650
154. Zhdanova I.V., Lynch H.J., and Wurtman R.J. Melatonin: A sleep-promoting hormone. Sleep 20 (1997) 899-907
155. Miyamoto M., Nishikawa H., Doken Y., et al. The sleeppromoting action of ramelteon (TAK-375) in freely moving cats. Sleep 27 (2004) 1319-1325
156. Yukuhiro N., Kimura H., Nishikawa H., et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 1027 (2004) 59-66
157. Hirai K., Kita M., Ohta H., et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 20 (2005) 27-37
158. (Suppl). Erman M., Seiden D., and Zammit G. Phase II study of the selective ML-1 receptor agonist TAK-375 in subjects with primary chronic insomnia. Abstract. Sleep 26 (2003) A298
159. Abstract. Roth T., Seiden D., van der Zee P., et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc 53 Suppl 4 (2005) 2-25
160. Boca Raton, Fla. Roth T., Seiden D., Weigand S., et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia. Program and abstracts of the 45th Annual Meeting of the New Clinical Drug Evaluation Unit. June 6-9, (2005)
161. (Suppl). Zammit G., Roth T., Erman M., et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Abstract. Sleep 28 (2005) A228 A229
162. Abstract. Zammit G., Schwartz H., Roth T., et al. Phase III study of ramelteon in a first-night-effect model of transient insomnia. Sleep Med 6 Suppl 2 (2005) S50-S51
163. Gray S.L., LaCroix A.Z., Hanlon I.T., et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 54 (2006) 224-230
164. (Suppl). Mendelson W.B. Clinical distinctions between longacting and short-acting benzodiazepines. J Clin Psychiatry 53 (1992) 4-7
165. Landi F., Onder G., Cesari M., et al., Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: An observational study. J Gerontol A Biol Sci Med Sci 60 (2005) 622-626
166. Hemmelgarn B., Suissa S., Huang A., et al. Benzodiazepine use and risk of motor vehicle crash in the elderly. JAMA 278 (1997) 27-31
167. Ensrud K.E., Blackwell T.L., Mangione C.M., et al., Study of Osteoporotic Fractures Research Group. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 50 (2002) 1629-1637
168. Lawlor D.A., Patel R., and Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: Cross sectional study. BMJ 327 (2003) 712-717
169. Stenbacka M., Jansson B., Leifman A., and Romelsjb A. Association between use of sedatives or hypnotics, alcohol consumption, or other risk factors and a single injurious fall or multiple injurious falls: A longitudinal general population study. Alcohol 28 (2002) 9-16
170. Allain H., Bentue-Ferrer D., Polard E., et al. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: A comparative review. Drugs Aging 22 (2005) 749-765
171. Schneeweiss S., and Wang P.S. Claims data studies of sedativehypnotics and hip fractures in older people: Exploring residual confounding using survey information. J Am Geriatr Soc 53 (2005) 948-954
172. Wang P.S., Bohn R.L., Glynn R.J., et al. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 49 (2001) 1685-1690
173. Griffiths R.R., and Johnson M.W. Relative abuse liability of hypnotic drugs: A conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66 Suppl 9 (2005) 31-41